JP6091435B2 - アデノ随伴ウイルス（ａａｖ）ベクターを用いたタンパク質の送達 - Google Patents

アデノ随伴ウイルス（ａａｖ）ベクターを用いたタンパク質の送達 Download PDF

Info

Publication number
JP6091435B2
JP6091435B2 JP2013554679A JP2013554679A JP6091435B2 JP 6091435 B2 JP6091435 B2 JP 6091435B2 JP 2013554679 A JP2013554679 A JP 2013554679A JP 2013554679 A JP2013554679 A JP 2013554679A JP 6091435 B2 JP6091435 B2 JP 6091435B2
Authority
JP
Japan
Prior art keywords
sequence
antibody
virus
aav
promoter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013554679A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014511180A (ja
JP2014511180A5 (enExample
Inventor
ベンジャミン バラージュ アレハンドロ
ベンジャミン バラージュ アレハンドロ
ボルチモア デイビッド
ボルチモア デイビッド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
California Institute of Technology
Original Assignee
California Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by California Institute of Technology filed Critical California Institute of Technology
Publication of JP2014511180A publication Critical patent/JP2014511180A/ja
Publication of JP2014511180A5 publication Critical patent/JP2014511180A5/ja
Application granted granted Critical
Publication of JP6091435B2 publication Critical patent/JP6091435B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • C07K16/118—Hepatitis C virus; GB virus C [GBV-C]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2013554679A 2011-02-22 2012-02-21 アデノ随伴ウイルス（ａａｖ）ベクターを用いたタンパク質の送達 Active JP6091435B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161445449P 2011-02-22 2011-02-22
US61/445,449 2011-02-22
US201161550123P 2011-10-21 2011-10-21
US61/550,123 2011-10-21
US201261598728P 2012-02-14 2012-02-14
US61/598,728 2012-02-14
PCT/US2012/025970 WO2012115980A1 (en) 2011-02-22 2012-02-21 Delivery of proteins using adeno-associated virus (aav) vectors

Publications (3)

Publication Number Publication Date
JP2014511180A JP2014511180A (ja) 2014-05-15
JP2014511180A5 JP2014511180A5 (enExample) 2015-04-09
JP6091435B2 true JP6091435B2 (ja) 2017-03-08

Family

ID=46721200

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013554679A Active JP6091435B2 (ja) 2011-02-22 2012-02-21 アデノ随伴ウイルス（ａａｖ）ベクターを用いたタンパク質の送達

Country Status (6)

Country Link
US (2) US8865881B2 (enExample)
EP (1) EP2678433B1 (enExample)
JP (1) JP6091435B2 (enExample)
CN (1) CN103492574B (enExample)
BR (1) BR112013021494B1 (enExample)
WO (1) WO2012115980A1 (enExample)

Families Citing this family (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2328446T5 (es) 2000-02-04 2014-02-27 Children's Hospital Research Foundation Uso de lipasa ácida lisosomal para tratar la aterosclerosis y enfermedades asociadas
US20100183558A1 (en) 2008-10-17 2010-07-22 Zhennan Lai Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
MX338426B (es) 2010-04-23 2016-04-15 Synageva Biopharma Corp Enzima de enfermedad del almacenamiento lisosomico.
US9309534B2 (en) 2010-07-12 2016-04-12 Universidad Autonoma De Barcelona Gene therapy composition for use in diabetes treatment
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DK2613798T4 (en) 2010-09-09 2018-04-16 Synageva Biopharma Corp USING LYSOSOMAL SUR LIPASE TO TREAT PATIENTS WITHOUT LYSOSOMAL SUR LIPASE
ES3005233T3 (en) 2010-10-01 2025-03-14 Modernatx Inc Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
EP2675472A4 (en) 2011-02-15 2014-09-17 Synageva Biopharma Corp METHOD FOR THE TREATMENT OF LACK OF LYSOSOMAL SAURER LIPASE
US8865881B2 (en) 2011-02-22 2014-10-21 California Institute Of Technology Delivery of proteins using adeno-associated virus (AAV) vectors
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2763701B1 (en) 2011-10-03 2018-12-19 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
JP2015501844A (ja) 2011-12-16 2015-01-19 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 修飾ヌクレオシド、ヌクレオチドおよび核酸組成物
US10093947B2 (en) * 2012-02-28 2018-10-09 Cornell University AAV-directed persistent expression of an anti-nicotine antibody gene for smoking cessation
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
WO2013151663A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of membrane proteins
US10004811B2 (en) * 2012-04-13 2018-06-26 Cornell University Development of a highly efficient second generation nicotine-conjugate vaccine to treat nicotine addiction
EP2900275A4 (en) 2012-09-29 2016-05-25 Univ Pennsylvania VETERINARY COMPOSITION AND METHOD FOR NONOPERATIVE CASTRATION
EP2914731B1 (en) * 2012-11-01 2019-09-11 California Institute of Technology Reversible gene expression
ES2921623T3 (es) 2012-11-26 2022-08-30 Modernatx Inc ARN modificado terminalmente
KR20230156146A (ko) * 2012-12-13 2023-11-13 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Ｄｎａ 항체 작제물 및 그 이용 방법
WO2015089492A2 (en) 2013-12-13 2015-06-18 The Trustees Of The University Of Pennsylvania Dna antibody constructs and method of using same
WO2014120975A1 (en) 2013-02-01 2014-08-07 California Institute Of Technology Antibody-mediated immunocontraception
US11332719B2 (en) 2013-03-15 2022-05-17 The Broad Institute, Inc. Recombinant virus and preparations thereof
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US9597658B2 (en) 2013-04-01 2017-03-21 Savannah River Nuclear Solutions, Llc Metal-organic framework templated synthesis of porous inorganic materials as novel sorbents
US10006049B2 (en) * 2013-05-16 2018-06-26 University Of Florida Research Foundation, Incorporated Hairpin mRNA elements and methods for the regulation of protein translation
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
US9884075B2 (en) 2014-01-16 2018-02-06 California Institute Of Technology Domain-swap T cell receptors
MX392639B (es) 2014-03-21 2025-03-24 Univ Leland Stanford Junior Vectores virales recombinantes para la integración de transgenes
MY186389A (en) * 2014-05-13 2021-07-22 Univ Pennsylvania Compositions comprising aav expressing dual antibody constructs and uses thereof
CN107043774B (zh) * 2014-09-25 2021-05-04 中国人民解放军第二军医大学东方肝胆外科医院 一种嵌合强启动子及其用途
CN107106689A (zh) * 2014-11-05 2017-08-29 沃雅戈治疗公司 用于治疗帕金森病的aadc多核苷酸
CN112410338A (zh) 2014-11-14 2021-02-26 沃雅戈治疗公司 调节性多核苷酸
BR112017011556A2 (en) 2014-12-01 2018-03-06 The Trustees Of The University Of Pennsylvania methods for generating a synthetic antibody, preventing or treating a disease, treating a subject of pathogen infection and a subject with cancer, product, nucleic acid molecule, and composition.
EP3242945B1 (en) 2015-01-07 2021-09-01 Universitat Autònoma de Barcelona Single-vector gene construct comprising insulin and glucokinase genes
US11000597B2 (en) * 2015-01-21 2021-05-11 University Of Florida Research Foundation, Incorporated Engineered receptor/ligand system for delivery of therapeutic agents
WO2016122791A1 (en) 2015-01-30 2016-08-04 The Regents Of The University Of California Spinal subpial gene delivery system
EP3283126B1 (en) 2015-04-16 2019-11-06 Emory University Recombinant promoters and vectors for protein expression in liver and use thereof
CN107708416B (zh) 2015-05-01 2021-06-29 Onl医疗股份有限公司 肽组合物和使用方法
EP4154914B1 (en) * 2015-05-07 2024-08-28 University of South Florida Modified ube3a gene for a gene therapy approach for angelman syndrome
EA201792500A1 (ru) 2015-05-13 2018-04-30 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Aav-опосредованная экспрессия антител против гриппа и способы их использования
US10016514B2 (en) 2015-05-15 2018-07-10 New Hope Research Foundation Polynucleotides, vectors and methods for insertion and expression of transgenes
US10966414B2 (en) 2015-05-26 2021-04-06 California Institute Of Technology Population control using engineered translocations
WO2017007994A1 (en) 2015-07-08 2017-01-12 American Gene Technologies International Inc. Hiv pre-immunization and immunotherapy
US10266844B2 (en) 2015-07-31 2019-04-23 California Institute Of Technology Activity-dependent expression of nucleic acids
EP3875593A1 (en) 2015-12-11 2021-09-08 California Institute of Technology Targeting peptides for directing adeno-associated viruses (aavs)
CN111569090A (zh) 2016-01-15 2020-08-25 美国基因技术国际有限公司 用于活化γ-δ T细胞的方法和组合物
US10137144B2 (en) 2016-01-15 2018-11-27 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
JP7153332B2 (ja) 2016-02-08 2022-10-14 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド Ｈｉｖワクチン接種および免疫療法
ES2911448T3 (es) 2016-03-09 2022-05-19 American Gene Tech Int Inc Vectores combinados y métodos para el tratamiento del cáncer
US20230279434A1 (en) * 2016-03-31 2023-09-07 University Of Cincinnati Methods and compositions for the treatment of als
WO2017180936A1 (en) * 2016-04-15 2017-10-19 The Trustees Of The University Of Pennsylvania Compositions for treatment of wet age-related macular degeneration
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
US20190224339A1 (en) * 2016-04-29 2019-07-25 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
US11976292B2 (en) 2016-06-08 2024-05-07 American Gene Technologies International Inc. Non-integrating viral delivery system and methods related thereto
EP3481418A4 (en) 2016-07-08 2020-03-11 American Gene Technologies International Inc. PRE-IMMUNIZATION AND IMMUNOTHERAPY OF HIV
US11583562B2 (en) 2016-07-21 2023-02-21 American Gene Technologies International Inc. Viral vectors for treating Parkinson's disease
KR102621134B1 (ko) * 2016-07-26 2024-01-04 코넬 유니버시티 알데히드 데히드로게나제 결핍의 치료를 위한 유전자 요법
CN106434575A (zh) * 2016-09-26 2017-02-22 中国动物卫生与流行病学中心 流感病毒作为表达载体的构建方法
AU2017336440B2 (en) 2016-09-28 2022-06-02 Cohbar, Inc. Therapeutic MOTS-c related peptides
EP3518966A1 (en) 2016-09-29 2019-08-07 GlaxoSmithKline Biologicals S.A. Compositions and methods of treatment of persistent hpv infection
EP3538546B1 (en) 2016-11-14 2025-01-08 Novartis AG Compositions, methods, and therapeutic uses related to fusogenic protein minion
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
CN110036020A (zh) 2016-12-09 2019-07-19 葛兰素史密丝克莱恩生物有限公司 具有狂犬病病毒抗原的黑猩猩腺病毒构建体
WO2018134265A1 (en) 2017-01-17 2018-07-26 Forrest Michael David Therapeutic inhibitors of the reverse mode of atp synthase
US11117930B2 (en) 2017-02-23 2021-09-14 Adrx, Inc. Peptide inhibitors of transcription factor aggregation
MX2019010275A (es) 2017-02-28 2019-10-15 Univ Pennsylvania Novedoso vector del subtipo f del virus adenoasociado (aav) y usos de este.
BR112019017697A2 (pt) 2017-02-28 2020-04-07 The Trustees Of The University Of Pennsylvania vacinas contra influenza baseadas em vetores de vírus adenoassociado (aav)
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
WO2018162748A1 (en) * 2017-03-10 2018-09-13 Genethon Treatment of glycogen storage disease iii
JP2020512815A (ja) * 2017-04-03 2020-04-30 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド フェニルケトン尿症を処置するための組成物および方法
WO2018191450A2 (en) 2017-04-14 2018-10-18 National Taiwan University Hospital Gene therapy for aadc deficiency
EP3634978A1 (en) 2017-06-07 2020-04-15 Adrx, Inc. Tau aggregation inhibitors
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
WO2018232359A1 (en) 2017-06-16 2018-12-20 American Gene Technologies International Inc. Methods and compositions for the activation of tumor cytotoxicity via human gamma-delta t-cells
US12116577B2 (en) * 2017-06-20 2024-10-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Codon-optimized human NPC1 genes for the treatment of Niemann-Pick type C1 deficiency and related conditions
RU2019143627A (ru) * 2017-06-28 2021-07-28 Юниверсити Оф Соус Флорида Модифицированный ген ube3a для генной терапии синдрома ангельмана
IL271845B2 (en) 2017-07-13 2024-06-01 Michael David Forrest Therapeutic modulators of the reverse mode of atp synthase
EP3655539A1 (en) 2017-07-21 2020-05-27 GlaxoSmithKline Biologicals S.A. Chikungunya virus antigen constructs
CN110945018A (zh) 2017-07-27 2020-03-31 诺华股份有限公司 抗脱落酶的trem2变体
TWI832036B (zh) 2017-08-03 2024-02-11 美商航海家醫療公司 用於aav之遞送之組合物及方法
BR112020002394A2 (pt) * 2017-08-09 2020-07-28 Bioverativ Therapeutics Inc. moléculas de ácidos nucleicos e usos das mesmas
EP3697902A1 (en) 2017-10-16 2020-08-26 GlaxoSmithKline Biologicals S.A. Enhanced promoter
KR20200066349A (ko) 2017-10-16 2020-06-09 글락소스미스클라인 바이오로지칼즈 에스.에이. 복제 가능 아데노바이러스 벡터
CA3084346A1 (en) 2017-10-16 2019-04-25 Glaxosmithkline Biologicals Sa Simian adenoviral vectors with two expression cassettes
CA3079048A1 (en) 2017-10-16 2019-04-25 Glaxosmithkline Biologicals Sa Adenoviral vectors with two expression cassettes encoding rsv antigenic proteins or fragments thereof
CN111819281B (zh) * 2017-10-23 2024-12-31 普利维尔治疗公司 用于神经变性疾病的基因疗法
US20200283800A1 (en) * 2017-10-23 2020-09-10 Prevail Therapeutics, Inc. Gene therapies for neurodegenerative diseases
BR112020012336A2 (pt) 2017-12-19 2021-03-30 Akouos, Inc. Administração de anticorpos terapêuticos mediada por aav para o ouvido interno
MX2020006225A (es) 2017-12-20 2020-12-07 Glaxosmithkline Biologicals Sa Constructos antigenicos del virus de epstein-barr.
CN108103104B (zh) * 2017-12-21 2021-07-06 北京锦篮基因科技有限公司 一种预防和治疗脉络膜新生血管相关眼部疾病的基因药物
BR112020014404A2 (pt) 2018-01-17 2020-12-29 Adrenas Therapeutics, Inc. Terapia gênica de vírus adenoassociado para deficiência de 21-hidroxilase
MA51842A (fr) * 2018-02-14 2020-12-23 Generation Bio Co Vecteurs d'adn non viraux et utilisations associées pour la production d'anticorps et de protéines de fusion
WO2019199841A1 (en) * 2018-04-09 2019-10-17 Cure Ahc, Inc. Aav-mediated delivery of atp1a3 genes to central nervous system
CN119662732A (zh) * 2018-05-08 2025-03-21 纽洛可科学有限公司 抗fam19a5抗体的腺相关病毒（aav）递送
EP3794126A1 (en) 2018-05-15 2021-03-24 Voyager Therapeutics, Inc. Compositions and methods for the treatment of parkinson's disease
WO2019222329A1 (en) 2018-05-15 2019-11-21 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
EP3793615A2 (en) 2018-05-16 2021-03-24 Voyager Therapeutics, Inc. Directed evolution of aav to improve tropism for cns
CN112638936A (zh) 2018-06-12 2021-04-09 葛兰素史密丝克莱恩生物有限公司 腺病毒多核苷酸和多肽
KR102925832B1 (ko) 2018-08-09 2026-02-11 바이오버라티브 테라퓨틱스 인크. 핵산 분자 및 비바이러스 유전자 치료를 위한 이의 용도
WO2020061079A1 (en) 2018-09-18 2020-03-26 California Institute Of Technology Engineered light-sensitive proteins
CN113383010B (zh) 2018-09-28 2025-09-09 沃雅戈治疗公司 具有经工程化改造的启动子的共济蛋白表达构建体及其使用方法
WO2020077165A1 (en) 2018-10-12 2020-04-16 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
US11352646B2 (en) 2018-11-05 2022-06-07 American Gene Technologies International Inc. Vector system for expressing regulatory RNA
US11965172B2 (en) 2018-11-05 2024-04-23 California Institute Of Technology DNA sequence modification-based gene drive
US20200148762A1 (en) * 2018-11-09 2020-05-14 Avamab Pharma Inc. Methods for regulating endogenous production of antibodies against infectious diseases
WO2020113199A1 (en) 2018-12-01 2020-06-04 International Aids Vaccine Initiative Recombinant hiv env polypeptides and their use
BR112021012249A2 (pt) * 2019-01-04 2021-09-08 Sangamo Therapeutics, Inc. Métodos e composições para o tratamento da doença de fabry
WO2020150065A1 (en) 2019-01-14 2020-07-23 California Institute Of Technology Methods and compositions for modulating appetite and intake of sodium
MX2021008542A (es) 2019-01-18 2021-11-12 Voyager Therapeutics Inc Métodos y sistemas para la producción de partículas de aav.
CN113518784A (zh) 2019-01-28 2021-10-19 科巴公司 治疗性肽
WO2020172465A1 (en) 2019-02-20 2020-08-27 Duke University Compositions and methods for the treatment of genetic diseases
WO2020190750A1 (en) 2019-03-15 2020-09-24 Modernatx, Inc. Hiv rna vaccines
US20220227875A1 (en) * 2019-05-31 2022-07-21 University Of Florida Research Foundation, Incorporated Vector-based therapy for thyroid disease
CN113966228A (zh) 2019-06-11 2022-01-21 葛兰素史密斯克莱生物公司 黏膜疫苗配制剂
US20230038502A1 (en) * 2019-06-11 2023-02-09 Shire Human Genetic Therapies, Inc. Adeno associated viral vector delivery of antibodies for the treatment of disease mediated by dysregulated plasma kallikrein
CN110423778B (zh) * 2019-07-26 2023-04-21 上海科技大学 一种逆行性重组2型腺相关病毒在感染螺旋神经元中的应用
JP2022545378A (ja) * 2019-08-15 2022-10-27 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア ＳＣＡ１の治療のための、導入遺伝子およびイントロン由来ｍｉＲＮＡを組み合わせた治療法
WO2021046155A1 (en) 2019-09-03 2021-03-11 Voyager Therapeutics, Inc. Vectorized editing of nucleic acids to correct overt mutations
EP4048800A1 (en) 2019-10-23 2022-08-31 Shire Human Genetic Therapies, Inc. Adeno-associated virus vectors based gene therapy for hereditary angioedema
IL294278A (en) * 2019-12-31 2022-08-01 Swanbio Therapeutics Ltd Improved aav-abcd1 constructs and use for the treatment or prevention of adrenoleukodystrophy (ald) and/or adrenomyeloneuropathy (amn)
WO2021169167A1 (en) * 2020-02-29 2021-09-02 Nanjing GenScript Biotech Co., Ltd. Method for treating coronavirus infections
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
WO2021247995A2 (en) 2020-06-04 2021-12-09 Voyager Therapeutics, Inc. Compositions and methods of treating neuropathic pain
CN111705069A (zh) * 2020-06-19 2020-09-25 武汉纽福斯生物科技有限公司 一种多神经营养因子联合表达载体及其应用
BR112023001456A2 (pt) 2020-07-27 2023-04-11 Voyager Therapeutics Inc Composições e métodos para o tratamento de distúrbios neurológicos relacionados à deficiência de beta glicosilceramidase
US20230285596A1 (en) 2020-07-27 2023-09-14 Voyager Therapeutics, Inc Compositions and methods for the treatment of niemann-pick type c1 disease
WO2022060916A1 (en) * 2020-09-15 2022-03-24 Regenxbio Inc. Vectorized antibodies for anti-viral therapy
EP4240389A4 (en) * 2020-11-04 2025-05-28 The Trustees of The University of Pennsylvania VIRAL VECTORS ENCODING DOG INSULIN FOR THE TREATMENT OF METABOLIC DISEASES IN DOGS
IL303317A (en) 2020-12-01 2023-07-01 Akouos Inc ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA
US20220186252A1 (en) 2020-12-16 2022-06-16 Takeda Pharmaceutical Company Limited Adeno associated viral vector delivery of antibodies for the treatment of disease mediated by dysregulated plasma kallikrein
WO2022157548A1 (en) 2021-01-24 2022-07-28 Forrest Michael David Inhibitors of atp synthase - cosmetic and therapeutic uses
US20240148903A1 (en) 2021-03-08 2024-05-09 Nanjing GenScript Biotech Co., Ltd. Delivery of antibody by using dual viral vector system
AR125143A1 (es) 2021-03-19 2023-06-14 Adrenas Therapeutics Inc Terapias génicas para la deficiencia de la 21-hidroxilasa
CN117940135A (zh) * 2021-08-06 2024-04-26 宾夕法尼亚大学理事会 用于治疗和预防错误折叠的蛋白的组合物和方法
EP4395808A4 (en) * 2021-09-01 2025-11-19 Jaguar Gene Therapy Llc Adenine-associated vectors and virions for the treatment of galactosemia and methods of use and manufacture
CN115772520B (zh) * 2021-09-08 2023-11-21 北京锦篮基因科技有限公司 用于治疗庞贝氏病的基因治疗构建体、药物组合物和方法
EP4415746A1 (en) 2021-10-12 2024-08-21 Bridgebio Gene Therapy LLC Methods and compositions for treating leukodystrophies
CN114085816B (zh) * 2021-10-26 2023-05-26 四川大学华西医院 一种标记临近星形胶质细胞的方法
CN114107390B (zh) * 2021-11-05 2023-10-24 中国科学院精密测量科学与技术创新研究院 一种用于表达抗体IgG1的rAAV载体及其应用
US20250049955A1 (en) 2021-11-17 2025-02-13 Voyager Therapeutics, Inc. Compositons and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
CN119365208A (zh) 2022-04-13 2025-01-24 巴塞罗那自治大学 通过表达klotho蛋白的基因疗法治疗神经肌肉疾病
WO2023240236A1 (en) 2022-06-10 2023-12-14 Voyager Therapeutics, Inc. Compositions and methods for the treatment of spinal muscular atrophy related disorders
US20250381304A1 (en) 2022-06-21 2025-12-18 Crispr Therapeutics Ag Methods and compositions for in vivo editing of stem cells
WO2023248145A1 (en) 2022-06-21 2023-12-28 Crispr Therapeutics Ag Compositions and methods for treating human immunodeficiency virus
CN116396983A (zh) * 2022-10-10 2023-07-07 苏州吉纳星辰生物技术有限公司 一种检测aav抗体滴度的方法
AU2023417630A1 (en) 2022-12-29 2025-05-15 Voyager Therapeutics, Inc. Compositions and methods for regulating mapt
AU2023427408A1 (en) 2023-02-02 2025-09-04 Voyager Therapeutics, Inc. Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
AU2024276475A1 (en) * 2023-05-22 2025-09-25 Fred Hutchinson Cancer Center Treatment of hsv-2 using a meganuclease
WO2025171001A1 (en) 2024-02-06 2025-08-14 Regeneron Pharmaceuticals, Inc. Compositions and methods for improved production of aav viral vectors
CN118045206B (zh) * 2024-04-12 2024-07-05 四川至善唯新生物科技有限公司 一种治疗脊髓型肌肉萎缩的药物组合物及其用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4937190A (en) 1987-10-15 1990-06-26 Wisconsin Alumni Research Foundation Translation enhancer
US6410300B1 (en) 1998-01-12 2002-06-25 The University Of North Carolina At Chapel Hill Methods and formulations for mediating adeno-associated virus (AAV) attachment and infection and methods for purifying AAV
WO2000015260A1 (en) * 1998-09-16 2000-03-23 Tanox, Inc. Anti-ige gene therapy
US6825945B1 (en) 1999-05-25 2004-11-30 Silverbrook Research Pty Ltd Method and system for delivery of a brochure
CA2413156C (en) * 2000-07-03 2009-08-18 Gala Design, Inc. Expression vectors
US7939059B2 (en) 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
EP2036985A1 (en) * 2002-04-09 2009-03-18 Nationwide Children's Hospital, Inc. Antibody gene transfer and recombinant AAV therefor
WO2004061113A1 (en) * 2003-01-07 2004-07-22 The University Of Hong Kong Adeno-associated virus mediated b7.1 vaccination synergizes with angiostatin to eradicate disseminated liver metastatic cancers
US7186699B2 (en) * 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
US7485291B2 (en) * 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
CA2526120A1 (en) 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
WO2005056762A2 (en) * 2003-12-05 2005-06-23 University Of Iowa Research Foundation Truncated cmv promoters and vectors containing same
EP1765846A4 (en) 2004-07-13 2010-02-17 Cell Genesys Inc AAV VECTOR COMPOSITIONS AND ITS USE IN PROCESSES FOR INCREASING IMMUNOGLOBULIN EXPRESSION
EP1807157A2 (en) * 2004-10-22 2007-07-18 Neurologix, Inc. Use of apoptosis inhibiting compounds in degenerative neurological disorders
US7943374B2 (en) * 2005-08-21 2011-05-17 Markus Hildinger Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb
CN101287838B (zh) * 2005-10-14 2016-03-30 美国政府健康及人类服务部，疾病控制和预防中心 狂犬病病毒组合物和方法
US20110110892A1 (en) * 2008-03-24 2011-05-12 President And Fellows Of Harvard College Vectors for delivering disease neutralizing agents
EP2108706A1 (en) * 2008-04-10 2009-10-14 Institut Pasteur New method for selecting compounds useful for treating and/or preventing microbial Shigella infection
US7943379B2 (en) 2008-04-30 2011-05-17 Nationwide Children's Hospital, Inc. Production of rAAV in vero cells using particular adenovirus helpers
US9132173B2 (en) * 2010-10-15 2015-09-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Expression vector for cholesterol 24-hydrolase in therapy of Huntington's disease
US8865881B2 (en) 2011-02-22 2014-10-21 California Institute Of Technology Delivery of proteins using adeno-associated virus (AAV) vectors

Also Published As

Publication number Publication date
US20120232133A1 (en) 2012-09-13
WO2012115980A1 (en) 2012-08-30
JP2014511180A (ja) 2014-05-15
US8865881B2 (en) 2014-10-21
US20150010578A1 (en) 2015-01-08
EP2678433B1 (en) 2017-05-03
EP2678433A4 (en) 2014-12-17
US9527904B2 (en) 2016-12-27
BR112013021494A2 (pt) 2017-05-30
EP2678433A1 (en) 2014-01-01
CN103492574B (zh) 2015-12-09
CN103492574A (zh) 2014-01-01
BR112013021494B1 (pt) 2021-09-08

Similar Documents

Publication Publication Date Title
JP2014511180A (ja) アデノ随伴ウイルス（ａａｖ）ベクターを用いたタンパク質の送達
KR20190135000A (ko) Aav 벡터를 기반으로 하는 인플루엔자 백신
KR20220012231A (ko) 완전-인간 번역 후 변형된 항체 치료제
US20250354169A1 (en) Adeno-associated virus (aav) delivery of anti-fam19a5 antibodies
JP2023531451A5 (enExample)
US20090035327A1 (en) Antibody Gene Transfer and Recombinant AAV Therefor
JP2025119015A (ja) 改変ウイルス粒子およびその使用
CN115398006A (zh) 用于治疗covid-19的ace2靶向组合物和方法
CN113913464B (zh) 一种表达载体、重组腺相关病毒及其在制备2019新型冠状病毒疫苗中的应用
WO2022165246A1 (en) Compositions and method of use of mutant ace2 decoy variants
CN103221063B (zh) 针对人类巨细胞病毒(cmv)gb蛋白质的高亲和力人类抗体
KR20230154074A (ko) 이중 바이러스 벡터 시스템을 이용한 항체 전달
KR20230093437A (ko) 안구 적응증을 위한 벡터화된 항-TNF-α 항체
Schnepp et al. Vector-mediated antibody gene transfer for infectious diseases
WO2021169167A1 (en) Method for treating coronavirus infections
WO2023030312A1 (zh) 一种用于艾滋病病毒感染基因治疗的基因序列构建体
US20230220088A1 (en) Anti-CCR5 Monoclonal Antibody-Based Compositions and Methods
Wagner et al. Influence of AAV vector tropism on long-term expression and Fc-γ receptor binding of an antibody targeting SARS-CoV-2
US20240216535A1 (en) Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof
US20260043046A1 (en) Cassettes of anti-complement component 3 antibody, vectorization and theraputic application
Pho Development of a novel therapeutic against coronaviruses
CN118240069A (zh) 一种特异性结合HAdV55的抗体或抗原结合片段及其应用
CA3216585A1 (en) Non-viral dna vectors expressing therapeutic antibodies and uses thereof
HK40078427A (en) Ace2-targeted compositions and methods for treating covid-19

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160425

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161031

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170110

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170207

R150 Certificate of patent or registration of utility model

Ref document number: 6091435

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250